Analytical Data
-
Gene name
RGS1
- Application
-
Alternative Names
1R20; BL34; IER1; IR20; B-cell activation protein BL34; Early response protein 1R20
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q08116
-
Expression Region
Met1~Lys209
-
Molecular Weight
54kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RGS1 (Regulator of G-protein Signaling 1) is a crucial protein involved in the modulation of G-protein signaling pathways, which play vital roles in various physiological processes including immune responses, cell proliferation, and neuronal signaling. Its importance stems from its ability to accelerate the GTPase activity of Gα subunits, thereby promoting the conversion of active GTP-bound forms to inactive GDP-bound forms, effectively terminating the signal transduction. Research on RGS1 has gained momentum due to its implications in various diseases, particularly in cancer and autoimmune disorders, where dysregulation of G-protein signaling can lead to aberrant cellular behaviors. Recombinant RGS1 protein has been studied extensively to delineate its structure-function relationships, elucidate its interaction with different G-protein subunits, and identify potential small molecule inhibitors that could modulate its activity. Such studies have significant therapeutic potential, as targeting RGS1 may offer new approaches for the treatment of conditions linked to disrupted G-protein signaling. Furthermore, the production of RGS1 as a recombinant protein facilitates high-throughput screening and biochemical assays, thereby advancing our understanding of its biological roles and enhancing drug discovery efforts aimed at modulating G-protein signaling pathways.
